On April 22, Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) disclosed the annual report of 2021. During the reporting period, the company achieved a revenue of 617 million yuan, a year-on-year increase of 16.1%; The net profit attributable to the parent company was 89.25 million yuan, a year-on-year decrease of 4.99%.
During the reporting period, the company continued to expand cooperation with well-known Chinese pharmaceutical enterprises, achieved phased results in national generic drug consistency evaluation and volume procurement, and the operating revenue continued to maintain a stable growth. Compared with the previous year, during the reporting period, the prices of wood pulp, corn starch, propylene oxide, stearic acid and other raw materials increased significantly, the cost of foreign trade export increased, and the goodwill impairment of subsidiaries was accrued, which slowed down the growth rate of the company’s profits. Qufu Tianli, a holding subsidiary, has a relatively single product structure and fierce market competition. The sharp rise in the price of main raw materials has put great pressure on its operating performance. In 2021, it achieved an operating revenue of 1003138 million yuan, an increase of 6.2% over the previous year, and a net profit of -6.7882 million yuan, a decrease of 6.3155 million yuan over the previous year. At the same time, at the end of the reporting period, the impairment test was conducted for the goodwill formed by the merger and acquisition of Qufu Tianli. Based on the principle of prudence, the provision for goodwill impairment was withdrawn for the first time, amounting to 6.1287 million yuan. The operating performance loss of Qufu Tianli company has affected the profit growth of the consolidated statements of listed companies to a certain extent.
During the reporting period, the company applied for 2 invention patents, and currently has 16 national invention patents (another 6 invention patents are in the trial stage); Four new pharmaceutical excipients (anhydrous calcium hydrophosphate, calcium hydrophosphate dihydrate, calcium sulfate, microcrystalline cellulose sodium carboxymethyl cellulose) have been added. At present, the company has 34 products with CDE registration numbers. The main products have been successfully associated with the preparations and are in the activated (a) state; Three new products (corn starch, sodium stearate fumarate and silicified microcrystalline cellulose) have obtained the DMF (drug management archives) filing number of FDA; A total of 14 products of the company have obtained the US DMF filing number, and 8 varieties have obtained the EU Express Certification (production quality certification of pharmaceutical excipients).
Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) said that the main battlefield of the company in the next few years is still in the field of pharmaceutical manufacturing, and the quality of imported auxiliary materials is fully consistent. Through the implementation of excellent performance management mode, strengthen total quality management and continuously improve the operation quality of enterprises.
